DOCSLIB.ORG

Congenital Anomalies Surveillance 2013-2014

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Congenital Anomalies Surveillance 2013-2014 NHS Greater Glasgow & Clyde CONGENITAL ANOMALIES SURVEILLANCE 2013-2014 REVIEW OF DATA RELATING TO CONGENITAL ANOMALIES DETECTED IN NHS GG&C BETWEEN 1 ST APRIL 2013 AND 31ST MARCH 2014 Dr. James Robins Source data provided by Hilary Jordan of Information Services Final 18th October 2014 Congenital Anomalies Report 2013-2014 Table of Contents Definitions ............................................................................................................................................... 5 Links to Previous Reports ........................................................................................................................ 6 GG&C Congenital Anomaly Report for 2012-2013 ............................................................................. 6 GG&C Congenital Anomaly Report for 2011-2012 ............................................................................. 6 1. Core Data ............................................................................................................................................ 7 1.1. Case based review........................................................................................................................ 7 1.2. Abnormality based review ......................................................................................................... 10 1.3. Maternal Age ............................................................................................................................. 11 1.4. Gender ....................................................................................................................................... 12 1.5. Multiple Pregnancy .................................................................................................................... 12 2. Point of Diagnosis.............................................................................................................................. 13 2.1. At Birth ....................................................................................................................................... 14 2.2. Within 1st week .......................................................................................................................... 16 2.3. Between 1-4 weeks .................................................................................................................... 16 2.4. Diagnosed after 1 month but within 1 year ............................................................................... 17 2.5. Diagnosis after 12 months ......................................................................................................... 17 2.6. Prenatal Diagnosis ...................................................................................................................... 17 2.7. Unknown .................................................................................................................................... 19 2.8. Post-mortem .............................................................................................................................. 19 3. Pregnancy Outcome .......................................................................................................................... 20 3.1. Live-birth .................................................................................................................................... 21 3.2. Stillbirth ...................................................................................................................................... 22 3.3. Spontaneous Fetal Loss .............................................................................................................. 23 3.4. Termination of Pregnancy .......................................................................................................... 23 4. Review by Defined Abnormality ....................................................................................................... 25 4.1. Endocrine & Metabolic Disorders .............................................................................................. 25 4.1.1. Congenital Hypothyroidism, (E0310; E0312; E039) ............................................................ 25 4.1.2. Congenital Hyper-insulinism, (E161, E169) ......................................................................... 25 4.1.3. In-born Errors of Metabolism ............................................................................................. 26 4.1.4. Disorders of Aromatic Amino-Acid Metabolism, (E70) ....................................................... 26 4.1.5. Disorders of Branched Chain Amino-Acid and Fatty Acid Metabolism, (E71) .................... 26 4.1.6. Other Disorders of Carbohydrate Metabolism ................................................................... 27 4.1.7. Cystic Fibrosis, (E840; E841; E849) ..................................................................................... 27 Jim Robins Final Page 2 Congenital Anomalies Report 2013-2014 4.2. Cranial & Spinal Abnormalities .................................................................................................. 28 4.2.1. Neural Tube Defect, (NTD) .................................................................................................. 28 4.2.2. Holoprosencephaly, (Q042) ................................................................................................ 30 4.2.3. Microcephaly, (Q02X) ......................................................................................................... 31 4.2.4. Hydrocephalus, (Q030, Q039) ............................................................................................. 32 4.2.5. Other Cranial & Spinal Abnormalities ................................................................................. 32 4.3. Cardiac & Circulatory ................................................................................................................. 33 4.3.1. Transposition of the Great Vessels, (Q203) ........................................................................ 35 4.3.2. Atrioventricular Septal Defect, (AVSD), (Q212) .................................................................. 35 4.3.3. Fallot’s Tetralogy, (Q213) .................................................................................................... 36 4.3.4. Pulmonary Valve Atresia & Stenosis, (Q220, Q221) ........................................................... 36 4.3.5. Hypoplastic Left Heart Syndrome, (Q234) .......................................................................... 37 4.3.6. Coarctation of the Aorta, (Q251) ........................................................................................ 37 4.3.5. Total Anomalous Pulmonary Venous Drainage, (TAPVD), (Q262) ...................................... 38 4.4. Congenital Malformations of the Respiratory System............................................................... 39 4.4.1. Choanal Atresia, (Q300) ...................................................................................................... 39 4.4.2. Laryngeal Atresia, (Q318) .................................................................................................... 39 4.4.3. Congenital Cystic Adenomatoid Malformation, (Q338, Q3380) ......................................... 39 4.4.4. Neuroenteric Cysts, Q341 ................................................................................................... 40 4.5. Face & Neck ............................................................................................................................... 41 4.5.1. Cleft Lip & Palate, (Q 352, Q3539, Q3599, Q3690, Q3699, Q378, Q3799) ......................... 41 4.5.2. Congenital Cavernous Lymphangioma, ‘Cystic Hygroma’, (D181, D1810). ........................ 42 4.5.3. Pierre-Robin Sequence, (Q870) .......................................................................................... 42 4.5.4. Congenital Cataracts, (Q120) .............................................................................................. 42 4.5.5. Other Face & Neck .............................................................................................................. 43 4.6. Gastrointestinal Abnormalities .................................................................................................. 44 4.6.1. Oesophageal Atresia, (Q391) .............................................................................................. 44 4.6.2. Imperforate Anus, Anal Stenosis & Anorectal Atresia, (Q4200, Q421, Q4290) .................. 44 4.6.3. Malrotation of Bowel, (Q433) ............................................................................................. 45 4.6.4. Other Gastrointestinal Abnormalities ................................................................................. 45 4.7. Renal & Urinary System ............................................................................................................. 46 4.7.1. Renal Agenesis and Other Reduction Defects, (Q600, Q601, Q602) .................................. 46 4.7.2. Cystic Kidney Disease (Q611, Q614, Q6141)....................................................................... 47 4.7.3. Congenital Obstructive Defects of Renal Pelvis & Malformation of Ureter, (Q62) ............ 47 4.7.4. Other Congenital Malformations of the Kidney, (Q63) ...................................................... 48 4.7.5. Other Congenital Anormalities, (Q64) ................................................................................ 49 4.7.6. Hypospadias,
Load more

Recommended publications
  • Autosomal Dominant Medullary Cystic Kidney Disease (ADMCKD)
    Autosomal Dominant Medullary Cystic Kidney Disease (ADMCKD) Author: Doctor Antonio Amoroso1 Creation Date: June 2001 Scientific Editor: Professor Francesco Scolari 1Servizio Genetica e Cattedra di Genetica, Istituto per l'infanzia burlo garofolo, Via dell'Istria 65/1, 34137 Trieste, Italy. [email protected] Abstract Keywords Disease name Synonyms Diagnostic criteria Differential diagnosis Prevalence Clinical description Management Etiology Genetic counseling References Abstract Autosomal dominant medullary cystic kidney disease (ADMCKD) belongs, together with nephronophthisis (NPH), to a heterogeneous group of inherited tubulo-interstitial nephritis, termed NPH-MCKD complex. The disorder, usually first seen clinically at an average age of 28 years, is characterized by structural defects in the renal tubules, leading to a reduction of the urine–concentrating ability and decreased sodium conservation. Clinical onset and course of ADMCKD are insidious. The first sign is reduced urine– concentrating ability. Clinical symptoms appear when the urinary concentrating ability is markedly reduced, producing polyuria. Later in the course, the clinical findings reflect the progressive renal insufficiency (anemia, metabolic acidosis and uremic symptoms). End-stage renal disease typically occurs in the third-fifth decade of life or even later. The pathogenesis of ADMCKD is still obscure and how the underlying genetic abnormality leads to renal disease is unknown. ADMCKD is considered to be a rare disease. Until 2000, 55 affected families had been described. There is no specific therapy for ADMCKD other than correction of water and electrolyte imbalances that may occur. Dialysis followed by renal transplantation is the preferred approach for end-stage renal failure. Keywords Autosomal dominant medullary cystic disease, medullary cysts, nephronophthisis, tubulo-interstitial nephritis Disease name Diagnostic criteria Autosomal dominant medullary cystic kidney The renal presentation of MCKD is relatively disease (ADMCKD) non-specific.
    [Show full text]
  • Renal Cystic Disorders Infosheet 6-14-19
    Next Generation Sequencing Panel for Renal Cystic Disorders Clinical Features: Renal cystic diseases are a genetically heterogeneous group of conditions characterized By isolated renal disease or renal cysts in conjunction with extrarenal features (1). Age of onset of renal cystic disease ranges from neonatal to adult onset. Common features of renal cystic diseases include renal insufficiency and progression to end stage renal disease (ESRD). Identification of the genetic etiology of renal cystic disease can aid in appropriate clinical management of the affected patient. Our Renal Cystic Disorders Panel includes sequence and deletion/duplicaton analysis of all 79 genes listed below. Renal Cystic Disorders Sequencing Panel AHI1 BMPER HNF1B NEK8 TCTN3 WDPCP ANKS6 C5orf42 IFT27 NOTCH2 TFAP2A WDR19 ARL13B CC2D2A IFT140 NPHP1 TMEM107 XPNPEP3 ARL6 CDC73 IFT172 NPHP3 TMEM138 ZNF423 B9D1 CEP104 INPP5E NPHP4 TMEM216 B9D2 CEP120 INVS OFD1 TMEM231 BBIP1 CEP164 IQCB1 PDE6D TMEM237 BBS1 CEP290 JAG1 PKD2 TMEM67 BBS10 CEP41 KIAA0556 PKHD1 TRIM32 BBS12 CEP83 KIAA0586 REN TSC1 BBS2 CRB2 KIF14 RPGRIP1L TSC2 BBS4 CSPP1 KIF7 SALL1 TTC21B BBS5 DCDC2 LZTFL1 SDCCAG8 TTC8 BBS7 GLIS2 MKKS TCTN1 UMOD BBS9 GLIS3 MKS1 TCTN2 VHL Disorder Genes Inheritance Clinical features/molecular genetics Bardet Biedl ARL6 AR Bardet-Biedl syndrome (BBS) is an autosomal syndrome BBS1 recessive multi-systemic ciliopathy characterized By BBS10 retinal dystrophy, oBesity, postaxial polydactyly, BBS12 leaning difficulties, renal involvement and BBS2 genitourinary abnormalities (2). Visual prognosis is BBS4 poor, and the mean age of legal Blindness is 15.5 BBS5 years. Birth weight is typically normal But significant BBS7 weight gain Begins within the first year. Renal BBS9 disease is a major cause of morBidity and mortality.
    [Show full text]
  • Congenital Kidney and Urinary Tract Anomalies: a Review for Nephrologists
    REVIEW ARTICLE Port J Nephrol Hypert 2018; 32(4): 385-391 • Advance Access publication 4 January 2019 Congenital kidney and urinary tract anomalies: a review for nephrologists Marina Vieira, Aníbal Ferreira, Fernando Nolasco Nephrology Department, Hospital Curry Cabral, Centro Hospitalar Lisboa Central, Lisboa, Portugal Received for publication: Sep 7, 2018 Accepted in revised form: Dec 7, 2018 ABSTRACT Kidney and urinary tract development disorder are two of the most prevalent congenital malformations and the main cause of chronic kidney disease in pediatric age patients. As such, it is very important that the neph‑ rologist understands these pathologies to improve transition and ensure a good continuity between pediatric and adult nephrological care. The purpose of this article is to present a brief review of congenital anomalies of the kidney and urinary tract (CAKUT). Kidney malformations are classified according to macroscopic and microscopic anatomic features, and are the result of the following abnormal renal developmental processes: malformations of the renal parenchyma, abnor‑ malities of the embryonic migration of the kidneys and abnormalities of the developing urinary collecting system. Keys words: congenital anomalies of the kidneys and urinary tract, dysplasia, ciliopathies, posterior urethral valves, vesicoureteral reflux. INTRODUCTION are more likely to require dialysis6. Kidney malforma‑ tions are classified according to macroscopic and micro‑ Kidney and urinary tract development disorders scopic anatomic features, and
    [Show full text]
  • Antenatal Diagnosis of Renal Tract Abnormalities and What I Tell My Patients
    Antenatal diagnosis of renal tract abnormalities and what I tell my patients Dr Lucy Kean Consultant fetal and maternal medicine Nottingham University Hospitals Referral groups • Previously affected pregnancy • Almost anything! • Family history • Dysplasia • Cystic disease • Sometimes severe reflux • Scan findings (largest group) • Can be anything at any gestation from 11 weeks when the first scan is usually performed What is visible and when? . • Fetal kidneys begin to function after 12 weeks • Bladder usually visible from 12 weeks and major obstruction can be visible at this stage • By 14 weeks urine output takes over amniotic fluid production • By 16 weeks urine output is such that upper renal tract obstruction can begin to cause problems and be visible • Nephrogenesis continues to term, so dysplasia can worsen during fetal life • Posterior urethral valves can present late 12-14 weeks • Bladder outflow obstruction/megacystis Lower urinary tract obstruction – Associations • Associated anomalies are common and include: – posterior urethral valves – Urethral agenesis – chromosomal anomalies – At 10-14 weeks – if the longitudinal bladder diameter is 7-15 mm risk of chromosomal defects ~25% • microcolon intestinal hypoperistalsis (MMIH) syndrome (Berdon syndrome) • megacystis megaureter syndrome • prune belly syndrome Treatment and prognosis: What do I tell patients? • A karyotype should be considered (CVS) • Prognosis can be variable. It can completely resolve or lead to progressive obstruction • A follow-up ultrasound is necessary • If the fetus is chromosomally normal – spontaneous resolution in about 90% if he bladder diameter is 7-15 mm – if the bladder diameter is >15 mm there is a very high likelihood of progressive obstructive uropathy • Management will depend on the whole clinical picture – Liquor volume – Other findings • Vesicoamniotic shunting may improve survival in severe cases, but survival with normal renal function is rare.
    [Show full text]
  • Drug Discovery for Polycystic Kidney Disease
    Acta Pharmacologica Sinica (2011) 32: 805–816 npg © 2011 CPS and SIMM All rights reserved 1671-4083/11 $32.00 www.nature.com/aps Review Drug discovery for polycystic kidney disease Ying SUN, Hong ZHOU, Bao-xue YANG* Department of Pharmacology, School of Basic Medical Sciences, Peking University, and Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing 100191, China In polycystic kidney disease (PKD), a most common human genetic diseases, fluid-filled cysts displace normal renal tubules and cause end-stage renal failure. PKD is a serious and costly disorder. There is no available therapy that prevents or slows down the cystogen- esis and cyst expansion in PKD. Numerous efforts have been made to find drug targets and the candidate drugs to treat PKD. Recent studies have defined the mechanisms underlying PKD and new therapies directed toward them. In this review article, we summarize the pathogenesis of PKD, possible drug targets, available PKD models for screening and evaluating new drugs as well as candidate drugs that are being developed. Keywords: polycystic kidney disease; drug discovery; kidney; candidate drugs; animal model Acta Pharmacologica Sinica (2011) 32: 805–816; doi: 10.1038/aps.2011.29 Introduction the segments of the nephron. Autosomal recessive polycystic Polycystic kidney disease (PKD), an inherited human renal kidney disease (ARPKD) results primarily from the mutations disease, is characterized by massive enlargement of fluid- in a single gene, Pkhd1[14]. Its frequency is estimated to be filled renal tubular and/or collecting duct cysts[1]. Progres- one per 20000 individuals. The PKHD1 protein, fibrocystin, sively enlarging cysts compromise normal renal parenchyma, has been found to be localized to primary cilia and the basal often leading to renal failure.
    [Show full text]
  • Case Report: Cystinuria and Polycystic Kidney Disease
    Case Report: Cystinuria and Polycystic Kidney Disease Ajaydeep Sidhu, MD, a Angela Mittal, MD, b Xamayta Negroni-Balasquide, MD, c Alex Constantinescu, MD, c Kristin Kozakowski, MDb Cystinuria and polycystic kidney disease are 2 genetic disorders that affect abstract the genitourinary tract but rarely together. This case report presents 2 pediatric patients diagnosed with polycystic kidney disease and cystinuria requiring surgical treatment. Both subjects presented acutely with stone disease. Imaging studies and stone analysis established the diagnoses. Although coexistence of these 2 conditions is rare, cystinuria should be considered in the differential diagnosis when evaluating patients with cystic disease who develop renal calculi. a Mount Sinai Medical Center, Miami Beach, Florida; bNicklaus Children’s Hospital, Miami, Florida; and cJoe CASE REPORT completely encrusted with stone DiMaggio Children’s Hospital, Hollywood, Florida debris; he therefore required a Dr Sidhu drafted the initial manuscript and Patient A is now a 16-year-old male percutaneous nephrolithotomy researched the topic presented; Dr Mittal assisted from Honduras with a 6-year history (PCNL) for removal of the encrusted in drafting the initial manuscript, revised and of nephrolithiasis who originally fi nalized the manuscript, and was involved in stents. Lost to follow-up again, presented to our institution acutely in the surgical care of the patients presented; the patient presented acutely in September 2012 with a symptomatic Drs Negroni-Balasquide and Constantinescu November 2014 with a large stone reviewed and revised the manuscript and 2-mm left ureterovesical junction burden, including a 2.2 × 1.4 × 1.0 cm conceptualized the case report, as well as calculus.
    [Show full text]
  • Hepatocyte Nuclear Factor 1B–Associated Kidney Disease: More Than Renal Cysts and Diabetes
    BRIEF REVIEW www.jasn.org Hepatocyte Nuclear Factor 1b–Associated Kidney Disease: More than Renal Cysts and Diabetes Jacobien C. Verhave, Anneke P. Bech, Jack F.M. Wetzels, and Tom Nijenhuis Department of Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands ABSTRACT Hepatocyte nuclear factor 1b (HNF1b)–associated disease is a recently recognized of this disease for the clinician. We illus- clinical entity with a variable multisystem phenotype. Early reports described an trate the heterogenic presentation of association between HNF1B mutations and maturity-onset diabetes of the young. HNF1b-associated disease on the basis These patients often presented with renal cysts and renal function decline that pre- of five selected patients, and we then ceded the diabetes, hence it was initially referred to as renal cysts and diabetes provide a concise review of the associated syndrome. However, it is now evident that many more symptoms occur, and diabe- signs and symptoms and their molecular tes and renal cysts are not always present. The multisystem phenotype is probably pathogenesis. attributable to functional promiscuity of the HNF1b transcription factor, involved in the development of the kidney, urogenital tract, pancreas, liver, brain, and para- HETEROGENIC PRESENTATION thyroid gland. Nephrologists might diagnose HNF1b-associated kidney disease in OF THE MULTISYSTEM patients referred with a suspected diagnosis of autosomal dominant polycystic kid- PHENOTYPE OF HNF1b- ney disease, medullary cystic kidney disease, diabetic nephropathy, or CKD of un- ASSOCIATED DISEASE known cause. Associated renal or extrarenal symptoms should alert the nephrologist to HNF1b-associated kidney disease. A considerable proportion of fi these patients display hypomagnesemia, which sometimes mimics Gitelman syn- The rst patient, a woman aged 39 years, drome.
    [Show full text]
  • Kidney Cysts Fact Sheet
    Last Reviewed August 2016 Page 1 Prevent, Detect, Support. Fact sheet Kidney Cysts Cystic kidney disease causes pockets Benign cysts are non-cancerous This fact sheet covers the three of clear, watery fluid (cysts) to form in sacs filled with clear, watery fluid. most common types of cystic the kidneys. The cysts slowly replace They range from small blisters to kidney disease: healthy kidney tissue causing the large sacs filled with several litres • Polycystic kidney disease kidneys to become larger. This makes of fluid. Having a few cysts is not it harder for your kidneys to work unusual, particularly as you become • Medullary cystic disease properly. older. These cysts don’t usually need • Medullary sponge kidney treatment and do not mean that you have cystic kidney disease. Cysts can develop if you have had long-term kidney problems, such as kidney failure and have been on dialysis for a long time. This is called Acquired Cystic Kidney Disease (ACKD). These cysts are not inherited Kidney cysts Normal kidney (passed on from your parents) and do not usually need treatment. What is polycystic kidney disease (PKD)? Polycystic Kidney Disease (PKD) is Autosomal Dominant PKD - This is Autosomal Recessive PKD - This is the most common inherited cystic the most common inherited form of a less common form of inherited PKD kidney disease. It causes the growth PKD. If you have autosomal dominant where both parents have to carry of thousands of cysts (fluid filled sacs) PKD you have a one in two chance this gene. In this case there is a one in your kidneys.
    [Show full text]
  • Cystic Kidney Diseases and During Vertebrate Gastrulation
    Pediatr Nephrol (2011) 26:1181–1195 DOI 10.1007/s00467-010-1697-5 REVIEW Cystic diseases of the kidney: ciliary dysfunction and cystogenic mechanisms Cecilia Gascue & Nicholas Katsanis & Jose L. Badano Received: 3 August 2010 /Revised: 15 September 2010 /Accepted: 15 October 2010 /Published online: 27 November 2010 # IPNA 2010 Abstract Ciliary dysfunction has emerged as a common Introduction factor underlying the pathogenesis of both syndromic and isolated kidney cystic disease, an observation that has Cystic diseases of the kidney are a significant contributor to contributed to the unification of human genetic disorders of renal malformations and a common cause of end stage renal the cilium, the ciliopathies. Such grouping is underscored disease (ESRD). This classification encompasses a number by two major observations: the fact that genes encoding of human disorders that range from conditions in which ciliary proteins can contribute causal and modifying cyst formation is either the sole or the main clinical mutations across several clinically discrete ciliopathies, manifestation, to pleiotropic syndromes where cyst forma- and the emerging realization that an understanding of the tion is but one of the observed pathologies, exhibits clinical pathology of one ciliopathy can provide valuable variable penetrance, and can sometimes be undetectable insight into the pathomechanism of renal cyst formation until later in life or upon necropsy (Table 1;[1]). elsewhere in the ciliopathy spectrum. In this review, we Importantly, although the different cystic kidney disorders discuss and attempt to stratify the different lines of are clinically discrete entities, an extensive body of data proposed cilia-driven mechanisms for cystogenesis, ranging fueled by a combination of mutation identification in from mechano- and chemo-sensation, to cell shape and humans and studies in animal models suggests a common polarization, to the transduction of a variety of signaling thread, where virtually all known renal cystic disease- cascades.
    [Show full text]
  • Ciliary Genes in Renal Cystic Diseases
    cells Review Ciliary Genes in Renal Cystic Diseases Anna Adamiok-Ostrowska * and Agnieszka Piekiełko-Witkowska * Department of Biochemistry and Molecular Biology, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland * Correspondence: [email protected] (A.A.-O.); [email protected] (A.P.-W.); Tel.: +48-22-569-3810 (A.P.-W.) Received: 3 March 2020; Accepted: 5 April 2020; Published: 8 April 2020 Abstract: Cilia are microtubule-based organelles, protruding from the apical cell surface and anchoring to the cytoskeleton. Primary (nonmotile) cilia of the kidney act as mechanosensors of nephron cells, responding to fluid movements by triggering signal transduction. The impaired functioning of primary cilia leads to formation of cysts which in turn contribute to development of diverse renal diseases, including kidney ciliopathies and renal cancer. Here, we review current knowledge on the role of ciliary genes in kidney ciliopathies and renal cell carcinoma (RCC). Special focus is given on the impact of mutations and altered expression of ciliary genes (e.g., encoding polycystins, nephrocystins, Bardet-Biedl syndrome (BBS) proteins, ALS1, Oral-facial-digital syndrome 1 (OFD1) and others) in polycystic kidney disease and nephronophthisis, as well as rare genetic disorders, including syndromes of Joubert, Meckel-Gruber, Bardet-Biedl, Senior-Loken, Alström, Orofaciodigital syndrome type I and cranioectodermal dysplasia. We also show that RCC and classic kidney ciliopathies share commonly disturbed genes affecting cilia function, including VHL (von Hippel-Lindau tumor suppressor), PKD1 (polycystin 1, transient receptor potential channel interacting) and PKD2 (polycystin 2, transient receptor potential cation channel). Finally, we discuss the significance of ciliary genes as diagnostic and prognostic markers, as well as therapeutic targets in ciliopathies and cancer.
    [Show full text]
  • Polycystic Kidney Disease Polycystic Kidney Disease (PKD) Is a Hereditary (Inherited) Disorder in Which Cysts Form in the Kidneys
    Understanding Polycystic Kidney Disease Polycystic Kidney Disease (PKD) is a hereditary (inherited) disorder in which cysts form in the kidneys. This causes your kidneys to enlarge and lose function over time. Patients with PKD also may have cysts in other organs in the body including the liver, ovaries, pancreas, spleen and large bowel. Cysts in these areas typically do not cause organ failure as they do in your kidneys. In more rare cases, PKD can also cause problems with the brain or heart, which can cause serious damage, including brain aneurysms. PKD is a fairly common disease with about 600,000 people having it in the United States1. That said, many people do not develop symptoms until they are in their 30’s or 40’s so this number is likely higher than the reported numbers state. There has been no research proving that this disease is more common in specific races or genders. Approximately 50% of patients with PKD will experience kidney failure by the time they are 60 and 60% by the time they are 701. Patients who have kidney failure will require a kidney transplant or dialysis. It is also important to note that not everyone with PKD will have kidney damage so severe that they will need dialysis in their lifetime. There is also a lot of research being done in this area that will hopefully result in even better results one day! Types of PKD As mentioned before, PKD is inherited and therefore runs in families. Parents pass the genes for this disease to their children.
    [Show full text]
  • Obstruction of the Urinary Tract 2567
    Chapter 540 ◆ Obstruction of the Urinary Tract 2567 Table 540-1 Types and Causes of Urinary Tract Obstruction LOCATION CAUSE Infundibula Congenital Calculi Inflammatory (tuberculosis) Traumatic Postsurgical Neoplastic Renal pelvis Congenital (infundibulopelvic stenosis) Inflammatory (tuberculosis) Calculi Neoplasia (Wilms tumor, neuroblastoma) Ureteropelvic junction Congenital stenosis Chapter 540 Calculi Neoplasia Inflammatory Obstruction of the Postsurgical Traumatic Ureter Congenital obstructive megaureter Urinary Tract Midureteral structure Jack S. Elder Ureteral ectopia Ureterocele Retrocaval ureter Ureteral fibroepithelial polyps Most childhood obstructive lesions are congenital, although urinary Ureteral valves tract obstruction can be caused by trauma, neoplasia, calculi, inflam- Calculi matory processes, or surgical procedures. Obstructive lesions occur at Postsurgical any level from the urethral meatus to the calyceal infundibula (Table Extrinsic compression 540-1). The pathophysiologic effects of obstruction depend on its level, Neoplasia (neuroblastoma, lymphoma, and other retroperitoneal or pelvic the extent of involvement, the child’s age at onset, and whether it is tumors) acute or chronic. Inflammatory (Crohn disease, chronic granulomatous disease) ETIOLOGY Hematoma, urinoma Ureteral obstruction occurring early in fetal life results in renal dys- Lymphocele plasia, ranging from multicystic kidney, which is associated with ure- Retroperitoneal fibrosis teral or pelvic atresia (see Fig. 537-2 in Chapter 537), to various
    [Show full text]